0001192482-13-000246.txt : 20131219
0001192482-13-000246.hdr.sgml : 20131219
20131219142923
ACCESSION NUMBER: 0001192482-13-000246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131217
FILED AS OF DATE: 20131219
DATE AS OF CHANGE: 20131219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TETRALOGIC PHARMACEUTICALS CORP
CENTRAL INDEX KEY: 0001361248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-889-9900
MAIL ADDRESS:
STREET 1: 343 PHOENIXVILLE PIKE
CITY: MALVERN
STATE: PA
ZIP: 19355
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Woody James N.
CENTRAL INDEX KEY: 0001553355
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36208
FILM NUMBER: 131288058
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-12-17
0001361248
TETRALOGIC PHARMACEUTICALS CORP
TLOG
0001553355
Woody James N.
C/O TETRALOGIC PHARMACEUTICALS CORP
343 PHOENIXVILLE PIKE
MALVERN
PA
19355
1
0
0
0
Common Stock
2013-12-17
4
P
0
243189
7.00
A
243189
I
See footnotes
Common Stock
2013-12-17
4
P
0
12159
7.00
A
255348
I
See footnotes
Common Stock
2013-12-17
4
P
0
6079
7.00
A
261427
I
See footnotes
Common Stock
2013-12-17
4
C
0
354663
A
616090
I
See footnotes
Common Stock
2013-12-17
4
C
0
17733
A
633823
I
See footnotes
Common Stock
2013-12-17
4
C
0
8866
A
642689
I
See footnotes
Common Stock
2013-12-17
4
C
0
227266
A
869955
I
See footnotes
Common Stock
2013-12-17
4
C
0
11363
A
881318
I
See footnotes
Common Stock
2013-12-17
4
C
0
5681
A
886999
I
See footnotes
Common Stock
2013-12-17
4
C
0
104118
7.00
A
991117
I
See footnotes
Common Stock
2013-12-17
4
C
0
5205
7.00
A
996322
I
See footnotes
Common Stock
2013-12-17
4
C
0
2602
7.00
A
998924
I
See footnotes
Common Stock
2013-12-17
4
X
0
2850
6.4022
A
1001774
I
See footnotes
Common Stock
2013-12-17
4
X
0
143
6.4022
A
1001917
I
See footnotes
Common Stock
2013-12-17
4
X
0
71
6.4022
A
1001988
I
See footnotes
Series B Convertible Preferred Stock
2013-12-17
4
C
0
354663
D
Common Stock
354663
0
I
See footnotes
Series B Convertible Preferred Stock
2013-12-17
4
C
0
17733
D
Common Stock
17733
0
I
See footnotes
Series B Convertible Preferred Stock
2013-12-17
4
C
0
8866
D
Common Stock
8866
0
I
See footnotes
Series C Convertible Preferred Stock
2013-12-17
4
C
0
227266
D
Common Stock
227266
0
I
See footnotes
Series C Convertible Preferred Stock
2013-12-17
4
C
0
11363
D
Common Stock
11363
0
I
See footnotes
Series C Convertible Preferred Stock
2013-12-17
4
C
0
5681
D
Common Stock
5681
0
I
See footnotes
Convertible Notes
7.00
2013-12-17
4
C
0
104118
D
Common Stock
104118
0
I
See footnotes
Convertible Notes
7.00
2013-12-17
4
C
0
5205
D
Common Stock
5205
0
I
See footnotes
Convertible Notes
7.00
2013-12-17
4
C
0
2602
D
Common Stock
2602
0
I
See footnotes
Series C Warrants
6.4022
2013-12-17
4
X
0
2850
D
Common Stock
2850
0
I
See footnotes
Series C Warrants
6.4022
2013-12-17
4
X
0
143
D
Common Stock
143
0
I
See footnotes
Series C Warrants
6.4022
2013-12-17
4
X
0
71
D
Common Stock
71
0
I
See footnotes
Directly owned by LVP Life Science Ventures, III, L.P.
Directly owned by LVP III Associates, L.P.
Directly owned by LVP III Partners, L.P.
Shares of Series B Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
Shares of Series C Convertible Preferred Stock were automatically converted to the same number of shares of Common Stock at the time of the Company's initial public offering which occurred on December 17, 2013.
The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
The reported securities are owned directly by each of LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates"), and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates, and Partners. The reporting person, a member of GP III, shares voting and investment power with respect to these shares but disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein
/s/ Richard L. Sherman, Attorney-In-Fact for James N. Woody
2013-12-19